Assessing AbbVie (ABBV) Valuation After FDA Approval Of Decnupaz For Ultra Rare Blood Cancer

Simply Wall St.05-29

AbbVie (ABBV) just received U.S. FDA approval for Decnupaz, the first antibody drug conjugate cleared to treat blastic plasmacytoid dendritic cell neoplasm, an ultra rare, aggressive blood cancer with...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2639620202?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/141885706-main-header/1756256222285","is_english":true,"pubTime":"2026-05-29 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639620202","market":"us","top_or_hot":-1,"title":"Assessing AbbVie (ABBV) Valuation After FDA Approval Of Decnupaz For Ultra Rare Blood Cancer","media":"Simply Wall St.","content":"<div>\n<p>AbbVie (ABBV) just received U.S. FDA approval for Decnupaz, the first antibody drug conjugate cleared to treat blastic plasmacytoid dendritic cell neoplasm, an ultra rare, aggressive blood cancer with...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/assessing-abbvie-abbv-valuation-after-fda-approval-of-decnup\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing AbbVie (ABBV) Valuation After FDA Approval Of Decnupaz For Ultra Rare Blood Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing AbbVie (ABBV) Valuation After FDA Approval Of Decnupaz For Ultra Rare Blood Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-29 20:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/assessing-abbvie-abbv-valuation-after-fda-approval-of-decnup><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbbVie (ABBV) just received U.S. FDA approval for Decnupaz, the first antibody drug conjugate cleared to treat blastic plasmacytoid dendritic cell neoplasm, an ultra rare, aggressive blood cancer with...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/assessing-abbvie-abbv-valuation-after-fda-approval-of-decnup\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/assessing-abbvie-abbv-valuation-after-fda-approval-of-decnup","article_id":"2639620202","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/141885706-main-header/1756256222285"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/assessing-abbvie-abbv-valuation-after-fda-approval-of-decnup","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2639620202","pubTimestamp":1780056600,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"AbbVie (ABBV) just received U.S. FDA approval for Decnupaz, the first antibody drug conjugate cleared to treat blastic plasmacytoid dendritic cell neoplasm, an ultra rare, aggressive blood cancer with limited options.\nSee our latest analysis for AbbVie.\nAbbVie’s shares trade at US$218.63 after a 10.59% 1 month share price return, even though the stock is still down 4.66% year to date. The 1 year total shareholder return of 21.62% points to stronger underlying momentum building over time.\nIf...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","IE000WAW04H5.SGD":"RQI GLOBAL \"I\" (SGD) INC A","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","BK4581":"高盛持仓","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","BK4588":"碎股","BK4550":"红杉资本持仓","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","IE000SO60NU8.SGD":"RQI GLOBAL \"I\" (SGDHDG) ACC A","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","ABBV":"艾伯维公司","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE000BZT7R73.USD":"RQI GLOBAL \"I\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","SG9999015978.USD":"利安颠覆性创新基金A","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC"},"translate_title":"FDA批准Decnupaz治疗超罕见血癌后评估艾伯维(ABBV)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1.5,"LABU":1.5},"content_text":"AbbVie (ABBV) just received U.S. FDA approval for Decnupaz, the first antibody drug conjugate cleared to treat blastic plasmacytoid dendritic cell neoplasm, an ultra rare, aggressive blood cancer with limited options. See our latest analysis for AbbVie. AbbVie’s shares trade at US$218.63 after a 10.59% 1 month share price return, even though the stock is still down 4.66% year to date. The 1 year total shareholder return of 21.62% points to stronger underlying momentum building over time. If this kind of healthcare progress interests you, it could be a good moment to scan beyond AbbVie and check out 35 healthcare AI stocks With AbbVie trading at US$218.63 and currently estimated to be at a 48% discount to intrinsic value, along with a 16% gap to the average analyst target, is this a clear sign of undervaluation or is the market already accounting for future growth? AdvertisementMost Popular Narrative: 12.3% Undervalued At a last close of $218.63 against a most followed fair value estimate of about $249, the leading narrative sees AbbVie trading below its modeled worth, with that view hinging heavily on execution in immunology and neuroscience.  Continued robust growth in immunology from Skyrizi and Rinvoq, buoyed by expanded prescribing across multiple high-need indications like IBD and dermatology, and further supported by ongoing launches and indication expansions, is likely to drive sustained top-line revenue growth and mitigate the impact of Humira's LOE.  Read the complete narrative. Curious what kind of revenue trajectory, margin uplift and future earnings multiple are baked into that fair value, and how much depends on a handful of flagship drugs? The narrative lays out a detailed earnings path, the assumed profitability reset and the valuation multiple it thinks the market could settle on, all tied to how convincingly AbbVie turns its pipeline into long term cash flows. Result: Fair Value of $249.43 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on risks such as tougher drug pricing rules and heavy dependence on a few key immunology and neuroscience products, which could still undermine those assumptions. Find out about the key risks to this AbbVie narrative. Another View: Earnings Multiple Sends A Different Signal That discounted cash flow view points to AbbVie trading below estimated fair value, but the earnings multiple tells a different story. At a P/E of 107.4x versus 16.4x for the US Biotechs industry and 20.5x for peers, and a fair ratio of 37x, the stock screens as expensive rather than cheap. For you, the question is whether that gap reflects real quality or simply raises the bar for future delivery. See what the numbers say about this price — find out in our valuation breakdown. NYSE:ABBV P/E Ratio as at May 2026Next Steps With such a mixed set of signals on value, risk and momentum, it makes sense to check the underlying data yourself and then quickly decide how it all stacks up for your portfolio using 2 key rewards and 5 important warning signs Looking for more investment ideas? If you stop with just one stock today, you may miss opportunities that fit your goals even better, so use the screener to keep your options open.  Pinpoint value, and see which companies combine quality fundamentals with attractive prices through 46 high quality undervalued stocks. Strengthen your portfolio’s foundations by focusing on financially robust businesses using the solid balance sheet and fundamentals stocks screener (46 results). Spot under-the-radar opportunities before the crowd by scanning the screener containing 22 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2639620202","isCrawlerRequest":true}